CONGRESS PRESENTATIONS

CONGRESS PRESENTATIONS

CROI 2025

San Francisco, California
March 9-12, 2025

  • ViiV-Sponsored Data

    • Cabotegravir Prevention

      Khan T, et al.

      PILLAR Month 12 clinical results: Zero HIV acquisition and high persistence with CAB LA for PrEP

    • Cabotegravir Treatment

      Altamirano J, et al.

      Clinical Outcomes Among Virologically Suppressed Women Receiving CAB+RPV LA in the OPERA Cohort

      Sax P, et al.

      Outcomes on Cabotegravir + Rilpivirine in Suppressed People with HIV (PWH) in TRIO Health US Cohort

      Sension M, et al.

      Long-term CAB+RPV LA Effectiveness in Virologically Suppressed Individuals in the OPERA Cohort

    • Dolutegravir-based Regimens

      Lackey PC, et al.

      Risk of Incident Hypertension with Common Antiretroviral Agent Combinations in the OPERA Cohort

    • Fostemsavir

      Ramgopal M, et al.

      Characteristics and Treatment Outcomes of People With HIV Prescribed Fostemsavir in The Trio Cohort

    • Pipeline

      Ferris R, et al.

      Temsavir treatment improves the recognition of HIV-1 infected cells by broadly neutralizing antibodies (bnAbs)

      Griesel R, et al.

      Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor

      Rogg L, et al.

      Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor

      Taiwo B, et al..

      VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study

      Wensel D, et al.

      Pre-clinical evaluation of effector function-enhanced variants of N6 bnAb

    • Other Disease-Related Content

  • ViiV-Supported & Collaborative Data

    • Cabotegravir Prevention

      Delany-Moretlwe S, et al.

      No increased risk for hypertension with CAB-LA compared to TDF/FTC for PrEP: results from HPTN 084

      Delany-Moretlwe S, et al.

      Performance of HIV RNA screening in the context of long-acting injectable cabotegravir in HPTN 084

      Fogel JM, et al.

      Use of DNA profiling to resolve discrepant HIV tests in the setting of injectable cabotegravir PrEP

      Grinsztejn B, et al.

      ImPrEP CAB Brasil: Enhancing PrEP Coverage with CAB-LA in Young Key Populations

      Grinsztejn B, et al.

      PrEP Choices Among Sexual and Gender Minorities in Brazil: the ImPrEP CAB-LA Study

      Hanscom B, et al.

      Estimation of prevention-effective CAB-LA concentrations among MSM/TGW in HPTN 083

      Landovitz RJ, et al.

      Response to HIV Treatment After Long-Acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083

      Magno L, et al.

      Patterns of First Choice, Switching, and Discontinuation of Oral and Injectable PrEP Among Adolescents from Sexual and Gender Minorities in Brazil

      Naidoo N, et al.

      Expanding the PrEP method market: Early insights from offering oral PrEP, PrEP ring, and injectable CAB PrEP for HIV prevention across five countries in Africa

      Nuwagaba-Biribonwoha H, et al.

      High incidence of curable sexually transmitted infections in HPTN 084: a tertiary analysis

      Phillips A, et al.

      Dynamic Choice HIV Prevention in the context of Injectable Cabotegravir (CAB-LA): a model-based cost-effectiveness analysis

      Richer D, et al.

      Depression and Suicide Risk Among Sexual and Gender Minorities: Insights from the ImPrEP CAB Brasil

      Wang H, et al.

      Impact of rapid long-acting prep scale-up among MSM: closing the unmet needs and towards ending HIV

      Wara N, et al.

      Acceptability of long-acting cabotegravir among pregnant and lactating people in South Africa

    • Cabotegravir Treatment

      Archary M, et al.

      Safety and Pharmacokinetics of long-acting Cabotegravir and Rilpivirine in children between 20-40kgs

      Dieterich M, et al.

      At Home CAB/RPV Provides Novel Approach to Achieve Viral Suppression in Adherence Challenged PWH

      Rana AI, et al.

      Decreasing oral induction duration in support of LAI ART use with hardly-reached populations

    • Dolutegravir-based Regimens

      Bamford A, et al.

      Baseline and emergent resistance profiles in the African paediatric CHAPAS-4 trial

      Blomme E, et al.

      Effectiveness and inflammatory markers after 144 weeks of switch to DTG/3TC in a randomized trial

      Di Gregorio S, et al.

      Changes in body composition in people with HIV switching to DTG/3TC or BIC/TAF/FTC

      Fombellida-Lopez C, et al.

      Impact of art simplification with dolutegravir and lamivudine on the HIV reservoir

      Kileel EM, et al.

      Risk of obesity, cardiometabolic disease and MACE after switch to an integrase inhibitor in REPRIEVE

      Momper JD, et al.

      PK and Safety of Chronic Dolutegravir Administration in Neonates Exposed to HIV-1 (IMPAACT 2023)

      Pineda J, et al.

      Switching to DTG/3TC vs. BIC/FTC/TAF and Steatotic Liver Disease: A Sub-study of PASODOBLE Trial

      Puertas MC, et al.

      Rapid clearance of the inducible HIV-1 reservoir after initiation of antiretroviral therapy

      Ryan R, et al.

      Dolutegravir-based antiretroviral therapy does not reduce plasma levonorgestrel or medroxyprogesterone acetate concentrations among contraceptive users living with HIV compared with HIV-negative controls

      Salinas TRW, et al.

      Immunological impact of short-term BCL-2 inhibition at ART initiation on SIV infected rhesus macaques

      Singh Y, et al.

      Drug interactions between dolutegravir (DTG) and escalating doses of rifampicin (RIF): DORIS study

      Tiraboschi JM, et al.

      Switch to DTG/3TC vs BIC/FTC/TAF (PASO-DOBLE study): Efficacy and Weight Changes by Predefined Subgroups

      Wu D, et al.

      Depression, Sleep, and Anxiety among pregnant and postpartum women using Dolutegravir and Efavirenz

    • Other Disease-Related Content

    • Translational Medicine

      Bolzenius J, et al.

      People with HIV exhibit structural brain changes following infection with SARS-COV-2

      Capoferri AA, et al.

      Early HIV-1 genetic diversity includes CTL and drug resistance mutations

      Chan P, et al.

      Neuronal Injury in a Subset of Individuals during Acute HIV Infection and After Immediate Treatment

      Dayananda A, et al.

      Delayed HIV-1 rebound correlates with enhanced CD8 T Cell activation in human trials

      dos Santos JC, et al.

      Genetic regulation of immune responses to CMV in spontaneous HIV controllers

      dos Santos JC, et al.

      Modulation of CCR5 Expression is Critical for the Maintenance of HIV Control and Reservoir Size

      Huber A, et al.

      Females With HIV Favor Interferon Responses Over Inflammation Upon TLR7 Activation

      Li Y, et al.

      Maximizing Benefits to Participants in Analytic Treatment Interruption Studies with bnAb infusions

      Mehta K, et al.

      Virulent HIV-1B: Clinical Challenges and Proteomic Insights

      Navas A, et al.

      Heterogeneity of PD-1 expression in People Living with HIV and its relationship with host and viral-related factors

      Ocampo F, et al.

      Cognitive Trajectories 1 year before and after COVID-19 in an AHI cohort

      Otten T, et al.

      Residual HIV viremia: association with reservoir, functional immunology and systemic inflammation

      Paul R, et al.

      Brain volume normalization after 96 weeks of ART started during acute HIV infection.

      Rios-Vazquez V, et al.

      Mitochondrial Gene Variants in VARS2 Influence HIV Reservoir and T Cells in European HIV Controllers

      Rios-Vazquez V, et al.

      Multi-omics Clustering Reveals Distinct HIV Reservoir Profiles in the 2000HIV Cohort

      Ruijten SDE, et al.

      Sex-based differences and genetic regulation of cytokine responses in people living with HIV

      Sacdalan C, et al.

      RV550: Safety and virological outcomes in blood and lymph nodes of N-803 with ART in acute infection

      Smith G, et al.

      Neutralization sensitivity of viral reservoir envelopes to broadly neutralizing antibodies VRC07-523LS and PGDM1400LS

      Takata H, et al.

      RV550: The effects of IL-15 super-agonist N-803 with ART in acute infection on T and NK cells

      Vadaq N, et al.

      ART Exposure and Accelerated Aging in PLHIV: Insights from Proteomic and Methylation Clocks

      van Eekeren LE, et al.

      Distinct Metabolic Perturbations Link Liver Steatosis and Incident CVD in Lean but Not Obese PLHIV

  • Plain Language Summaries

    View plain language summaries of select congress presentations. These summaries include non-technical language and are formatted to help make the information accessible to a wider audience.

ViiV Medical Webinar asset

2025 Post CROI Conference

Scientific Engagement Webinar - with panel discussion and audience Q&A

My MSL

Enter zip code to find your MSL contact.